TCT-203 Mid-term Follow-Up Results of Drug-eluting Stent Implantations Following Rotational Atherectomy for Heavily Calcified Lesions: Impact of the Second-generation Drug-eluting Stent  by Fuku, Yasushi et al.
www.jacctctabstracts2013.com TUESDAY, OCTOBER 29, 2013, 3:30 PM–5:30 PMsuccesses were achieved in 95% of cases. Type B2/C lesions were treated in 63% of
cases. Long-term follow-up showed a combined major adverse cardiac events rate
(death, MI and target lesion revascularization (TLR)) of 11%. All cause mortality
was noted in 5%, cardiac mortality in 1%, MI in 6% and stroke in 1%. Finally, TLR
and target vessel revascularization were noted in 3% and 4% of cases respectively.
The independent predictors of MACE were cancer (Odds Ratio (OR): 6.55 [2.64,
16.28]; p<0.001), respiratory disease (OR: 4.41 [1.68, 10.47]; p<0.001), post-
dilation (OR: 2.85 [1.19-6.80]; p¼ 0.018) and type C lesions (OR: 1.91 [1.02-3.56];
p¼ 0.042).
Conclusions: In this real life cohort, the treatment of highly complex lesions with the
Osiro Stent was associated with excellent long-term results. Further randomized trials
are warranted to conﬁrm these ﬁndings.TCT-200
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Background: Long term safety and efﬁcacy of the Elixir DESyne BD Novolimus
Eluting Coronary Stent System (NECSS), a Co-Cr stent with a bioabsorbable polymer
compared to the control Endeavor Zotarolimus Eluting Coronary Stent System is not
known
Methods: 149 patients were randomized 3:1, either to the Elixir DESyne BD
Novolimus Eluting CSS loaded with 5mcg per mm of stent length of Novolimus,
a sirolimus metabolite, eluted via a bioabsorbable polylactide-based polymer, or to
the Endeavor Zotarolimus-eluting CSS (ZECSS) loaded with 10mcg per mm of
stent length of Zotarolimus eluted via a durable phosphoryl choline polymer. All
patients were analyzed for the primary endpoint of in-stent late lumen loss (LLL)
assessed by qualitative coronary angiography (QCA) at 6 months. Moreover, all
patients underwent evaluation for the secondary endpoints including the Device-
orientated Composite Endpoint (DoCE) deﬁned as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion
revascularization; clinically-indicated Target Vessel Revascularization (TVR), and
stent thrombosis at 1, 6, 9, and 12 months and annually through 5 years. Lesions
were also evaluated for angiographic endpoints at 6 months including: in-segment
LLL, percent diameter stenosis, minimal lumen diameter post-procedure, and
angiographic binary restenosis (ABR) (50%). A subset of patients underwent
intravascular ultrasound (IVUS) evaluation including percent (%) neointimal
obstruction at 6 months.
Results: The study met the primary endpoint demonstrating both non-inferiority and
superiority of the DESyne BD compared to the control (0.120.15 vs 0.670.47,
p<0.001), additionally, in-stent ABR was signiﬁcantly lower for DESyne BD (0% vs
7.9%, p¼0.003). Excellent clinical results at 6 months were demonstrated for both
devices (DoCE 2.7% vs. 3.2%, p¼ 1.00). Sustained low clinical event rates were
observed at 12 months and 24 months (DoCE 2.7% vs 3.2% p¼1.0)
Conclusions: The DESyne BD NECSS demonstrated sequential non-inferiority and
superiority over a durable polymer Endeavor ZECSS for in-stent late lumen loss at 6
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Background: The outcome of small-vessel stenting with the second-generation drug-
eluting stents (DES) remains uncertain. Stents deployed in small arteries, have
a higher metal-to-artery ratio; this may increase the risk of restenosis. Speciﬁc attri-
butes of stent design, including strut thickness and eluting drug, inﬂuence stent
performance characteristics, particularly in smaller coronary vessels.
Methods: This study is a single-center, retrospective observational study. From April
2009 to December 2011, 264 patients with small vessel coronary artery disease wereJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstrtreated with 2.5mm DES implantation, which consisted of 225 patients with 2.5mm
Everolimus eluting stent (EES) implantation and 39 patients with 2.5mm Biolimus
eluting stent (BES) implantation. Out of these patients, 226 patients underwent follow-
up coronary angiography at eight months post-PCI. We evaluated the results of those
226 patients.
Results: Though pre-PCI reference vessel diameter were less in EES group than BES
group (EES:2.110.34, BES:2.250.28 mm, p<0.05), there were no signiﬁcant
difference in patient characteristics, pre-PCI minimal lumen diameter(MLD)
(0.690.36, 0.710.41 mm) and angiographic percent diameter sten-
osis(PDS)(67.817.1, 69.318.7 %). Post-PCI MLD of BES group were smaller than
those of EES group. (1.960.31, 2.080.31 mm p<0.05) Post-PCI PDS(11.010.9,
8.310.5 %) and acute gain(1.310.46, 1.440.47 mm) were similar in both groups.
At follow-up coronary angiography eight months later, there were no signiﬁcant
difference in MLD(1.850.55, 2.020.59 mm), PDS(21.620.7, 19.417.1 %),
binary restenosis (17 cases; 7.6%, 3 cases; 7.7%) and target lesion revacularization
(7 cases; 3%, 0 case; 0%).
Conclusions: Though pre-PCI lesion characteristics of BES group were a little better
than those of EES group, there were no signiﬁcant difference between EES and BES
in the middle-term outcome of small-vessel stenting.TCT-202
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Background: Pioglitazone is widely used for glycemic control in patients with type-2
diabetes mellitus (DM), and is associated with a lower risk of cardiovascular events
according to a meta-analysis of randomized trials. To evaluate the effect of pioglita-
zone on ischemic cardiovascular events in Japanese patients with DM and coronary
artery disease, after drug-eluting stents (DESs) implantation, the 12-month data from
the Japan-Drug Eluting Stents Evaluation; a Randomized Trial (J-DESsERT) was
analyzed.
Methods: In this prospective, multicenter trial, 3,533 patients were randomized 1:1
to undergo coronary stenting with Sirolimus-eluting stents or Paclitaxel-eluting
stents. Lesion lengths were 46 mm, with vessel diameters from 2.5 mm to 3.75
mm. Randomization was stratiﬁed based on the presence or absence of DM.
Deﬁnitions for allocation into the DM group at the time of this trial were: 1.
Previous DM diagnosis; 2. Currently on diabetic medication (oral hypoglycemic
drugs or insulin injections); 3. HbA1c (Japan diabetes society [JDS])  6.5% within
30 days before the procedure. Patients who met one or more of the above criteria
were allocated to the DM group. A total of 1,705 patients (48%) with DM were
analyzed from the J-DESsERT trial.
Results: Target vessel revascularization (TVR) is deﬁned as any ischemia-driven
repeat percutaneous coronary intervention (PCI), target vessel bypass surgery, all
death, myocardial infarction (Q wave and non-Q wave), and cerebrovascular
accident (stroke, transient ischemic attack). Including TVR, major adverse cardiac
cerebrovascular events (MACCE) occurred in only 22 of 357 patients (6.33%)
receiving pioglitazone at 12 months. Conversely, substantially more MACCE
events occurred in the group not receiving the pioglitazone, 152 of 1,348 patients
(11.6%, p¼<0.01).
Conclusions: Pioglitazone is associated with a signiﬁcantly lower MACCE rate at
both 8 and 12 months, in Japanese patients with DM, post-DES implantation.TCT-203
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Background: The purpose of this study was to evaluate the impact of second-
generation DES (2nd DES) as compared with ﬁrst-generation DES (1st DES) in
patients treated with DES implantation following rotational atherectomy (RA) for
heavily calciﬁed lesions.
Methods: From December 2003 to August 2012, 616 lesions in 492 patients were
treated with 1st DES (Sirolimus-eluting stent [SES] or Paclitaxel-eluting stent [PES])
or 2nd DES (Everolimus-eluting stent [EES] or Biolimus-eluting stent [BES])
implantations following RA exclusively and successfully. Of these lesions, 389
lesions in 312 (63.4%) patients who had undergone 8-month angiographic follow-up
were analysed.acts/POSTER/Bare Metal and Drug-Eluting Stent Studies B65







SResults: There were no signiﬁcant differences in baseline characteristics except
angulated lesion (1st DES vs. 2nd DES: 12.3% vs. 29.2%, p < 0.001),
burr-to-artery ratio (0.62 vs. 0.59, p < 0.001), and IVUS use (42.8% vs. 81.7%, p
< 0.001). In all patients, no signiﬁcant differences were observed between 2 groups
in the restenosis and TLR rates (21.2 vs. 14.2%, p ¼ 0.12 and 17.1% vs. 11.7%, p
¼ 0.22, respectively). However, the restenosis and TLR rates of 2nd DES were
signiﬁcantly lower than those rates of 1st DES in non-HD patients (19.0% vs.
7.9%, p ¼ 0.015 and 13.9% vs. 5.6%, p ¼ 0.047, respectively). In contrast, those
rates were similar between 2 groups in HD patients (30.2 vs. 32.3%, p ¼ 1.0 and
30.2% vs. 29.0%, p ¼ 1.0, respectively). Table shows quantitative angiographic
outcomes.
Conclusions: The mid-term angiographic results of 2nd DES might be superior to
those of 1st DES in non-HD patients treated with DES implantation following RA.TCT-204
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Background: Differences in enrollment criteria and protocol requirements are thought
to affect patient representation and outcomes from premarket and postmarket
surveillance (PMS). We assessed differences between premarket vs. PMS trials
assessing implantation of the Endeavor-zotarolimus eluting stent (E-ZES).
Methods:We analyzed data from 2132 and 4357 E-ZES treated subjects (ENDEAVOR
premarket and PROTECT PMS trials, respectively). We analyzed differences in 3-year
outcomes and adjusted them for differences in baseline characteristics.
Results: The two groups differed signiﬁcantly in baseline characteristics. However,
the rates of 3-year major adverse cardiac event (MACE), major adverse cardiac and
cerebrovascular event (MACCE) and target vessel failure (TVF), were similar
(12.67% vs. 13.88%, p¼0.191; 11.88% vs. 12.68%, p¼0.369; and 13.81% vs.
13.01%, p¼0.419, respectively). PMS trials had less clinically driven target vessel
revascularizations (CD-TVR, p<0.001) and more myocardial infarctions (MI,
p¼0.005). Differences emerged at 8 moths and immediately post-procedurally,
respectively. After propensity score adjustment, CD-TVR rates no longer differed
signiﬁcantly (HR 0.72, 95% CI 0.51-1.01).Conclusions: Premarket and PMS trials assessing E-ZES implantation had similar
3-year composite outcomes. Differences in CD-TVR were attributed to different
protocol requirements and in MIs to different outcome deﬁnitions. It is yet to be
determined if these settings reﬂect everyday practice.B66 JACC Vol 62/18/Suppl B j October 27–November 1, 2013TCT-205
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Background: Percutaneous coronary intervention (PCI) of moderate and severely
calciﬁed lesions has been described as a predictor of worse outcomes when bare-
metal stents or ﬁrst-generation drug-eluting stents (DES) have been used. Little is
known about the impact of coronary calciﬁcation on outcome after PCI with modern
DES.
Methods: 14,134 patients treated with a biolimus A9-eluting stent with a biodegrad-
able polymer (Nobori, Terumo, Japan) were pooled from 2 all-comer registries
(Nobori-2 and e-Nobori). An independent clinical event committee adjudicated all
adverse events and an independent corelab analyzed baseline and adverse events'
angiograms. Patients were divided into 2 groups based on whether or not PCI was
performed on moderate/severely calciﬁed lesions. Target lesion failure (TLF), deﬁned
as cardiac death, target vessel-related myocardial infarction and target lesion revas-
cularization, and stent thrombosis were assessed at 1 year.
Results: Overall, 4321 patients (30.6%) had moderate/severe coronary calciﬁcation.
Patients with calciﬁed lesions were older and had a higher rate of diabetes mellitus,
hypertension, renal failure, peripheral arterial disease and previous bypass surgery, but
less commonly presented with an acute coronary syndrome. Patients with calciﬁed
lesions more commonly required multivessel treatment and needed longer stents. Pre-
and post- dilatations were more often performed in the calciﬁed lesions group.
Rotational atherectomy or cutting balloons were used in only 5.49%. Preliminary data
at 1-year follow-up (currently available in 9,089 patients) revealed low rates of TLF
and stent thrombosis, but both were signiﬁcantly higher in patients with moderate/
severe calciﬁcation (TLF in 5.03% vs. 2.83%, p<0.001, stent thrombosis in 0.72% vs.
0.34%, p¼0.03). By multivariate analysis, the presence of moderate/severe calciﬁ-
cation was a strong independent predictor of TLF at 1-year (OR1.77, 95%CI 1.23-
2.55, p¼0.002).
Conclusions:Moderate/severe coronary calciﬁcation independently predicts increased
rates of TLF at 1-year after PCI with the biolimus A9-eluting Nobori stent, but overall
stent performance remains excellent and event rates are surprisingly low.
TCT-206
Angiographic efﬁcacy of Resolute Zotarolimus- or Everolimus- Eluting Stent
versus Sirolimus-Eluting Stent Implantation in Long or Diabetic Coronary
Artery Disease: Result from LONG-DES III, IV, and ESSENCE-DIABETES
trials
Seung-Whan Lee1, Jung-Min Ahn1, Young-Rak Cho2, Seungbong Han2,
Jeong Yoon Jang3, Soo-Jin Kang1, Won-Jang Kim1, Young-Hak Kim4,
Chang Hee Kwon5, Jong-Young Lee1, Cheol Whan Lee1, Woo Seok Lee6,
Nae Hee Lee7, Duk-Woo Park1, Gyung-Min Park8, Seong-Wook Park1, John Seo9,
Seung-Jung Park1
1Asan Medical Center, Seoul, Korea, Republic of, 2Asan Medical Center, Seoul,
Seoul, 3Heart Institute, University of Ulsan College of Medicine, Asan Medical
Center, N/A, 4Asan medical center, Seoul, Korea, Republic of, 5Asan medical Center,
Seoul, Korea, Republic of, 6AMC, Seoul, Korea, Republic of, 7Soonchunhyang
University Hospital, Bucheon, Korea, Republic of, 8Daejeon St. Mary's Hospital,
Daejeon, Korea, Republic of, 9SoonChunHyang, Bucheon, Korea, Republic of
Background: This study was performed to assess angiographic outcomes of newer
generation drug-eluting stent (NDES) [everolimus-(EES) or resolute zotarolimus-
eluting stents (R-ZES)] versus sirolimus-eluting stents (SES) for long or diabetic
coronary artery disease.
Methods: Patients level data from three randomized trials (Long-DES III, IV and
ESSENCE-DIABETES) were pooled to estimate angiographic efﬁcacy of EES or
R-ZES versus SES. A total of 1,250 patients underwent EES or R-ZES (NDES group,
n¼623) and SES (SES group, n¼627). We evaluated angiographic restenosis after
DES implantation at follow-up duration.
Results: Follow-up angiography was done in 919 patients (73.5%). In-stent (3.0% vs.
4.4%, p¼0.28) and in-segment restenosis (5.0% vs. 5.2%, p¼0.86) was also statis-
tically not different between NDES vs. SES group. In-segment restenosis was similar
between NDES vs. SES group in diabetics (3.9% vs. 6.7%, p¼0.22), > 30 mm long
stent implantation patients (6.9% vs. 6.0%, p¼0.64), and  2.5 mm small vessel
disease (6.3% vs. 8.7%, p¼0.50). However, lesion length > 40 mm showed signiﬁ-
cantly higher angiographic restenosis compared to lesion length  40 mm in both
stents groups (NDES: 10.2% vs. 3.2 %, p¼0.003: SES: 9.0 % vs. 3.9%, p¼0.03).
Conclusions: Newer generation DES showed comparable angiographic outcomes
with SES in patients at high risk of restenosis and effectively reduced angiographic
restenosis across all high risk lesion subsets, but their angiographic efﬁcacies were
attenuated in > 40 mm lesion length in both stent groups.j TCT Abstracts/POSTER/Bare Metal and Drug-Eluting Stent Studies
